TMX-2039

• Description:

  TMX-2039 is a pan-CDK inhibitor for both cell cycle CDKs (CDK1, CDK2, CDK4, CDK5 and CDK6) and transcriptional CDKs (CDK7 and CDK9), with IC50s of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5 and 25 nM, respectively. TMX-2039 acts as a Ligands for Target Protein for PROTACs[1].

• UNSPSC:

  12352005

• Target:

  CDK; Ligands for Target Protein for PROTAC

• Related Pathways:

  Cell Cycle/DNA Damage; PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.42

• Smiles:

  CS(=O)(N1CCC(CC1)NC2=NC=C(C(NC3=CC=CC(F)=C3C(N)=O)=N2)Br)=O

• Molecular Formula:

  C17H20BrFN6O3S

• Molecular Weight:

  487.35

• References & Citations:

  [1]Mingxing Teng, et al. Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angew Chem Int Ed Engl. 2020 Aug 10;59 (33) :13865-13870.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9

• CAS Number:

  2488892-01-7